Metronidazol Ziaja (Metronidazole)

Metronidazole penetrates the skin’s microbial cells and, under anaerobic conditions, its nitro group is reduced to reactive intermediates. These free radicals damage DNA and essential proteins of anaerobic bacteria and protozoa, leading to cell death and resolution of infection and inflammation.

The specific dosing regimen for Metronidazol Ziaja is determined by the prescribing healthcare professional based on the indication, severity of the condition, and patient factors. Patients should follow the instructions provided by their prescriber and the product label.

Safety data for topical metronidazole in pregnancy and lactation are limited. Healthcare providers should evaluate the potential benefits and risks before prescribing to pregnant or nursing individuals. If used, it should be applied to the smallest area necessary and for the shortest duration required.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and necessary import documentation.

Metronidazol Ziaja belongs to the nitroimidazole class, offering anti‑anaerobic and anti‑inflammatory effects. Compared with antibiotics like clindamycin or azelaic acid, metronidazole provides a distinct mechanism targeting anaerobic bacteria and may be preferred when those agents are ineffective or contraindicated.

Store the product below 25 °C in its original packaging, protecting it from moisture, heat and direct sunlight. Ensure the container is tightly closed to maintain product stability and prevent contamination.

Apply a thin layer of the cream or gel to the affected skin area once or twice daily, as directed by the prescriber. Wash hands before and after application, and avoid contact with eyes, mouth and open wounds.

Serious risks include severe allergic reactions such as anaphylaxis, Stevens‑Johnson syndrome, and methemoglobinemia. If any signs of systemic toxicity, widespread rash, blistering, or difficulty breathing occur, discontinue use immediately and seek medical attention.

Individuals with known hypersensitivity to metronidazole or any component of the formulation should avoid using the product. It is also contraindicated on extensively damaged or ulcerated skin, and caution is advised in patients with a history of severe allergic reactions.